Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.

Huhn GD, Wilkin A, Mussini C, Spinner CD, Jezorwski J, El Ghazi M, Van Landuyt E, Lathouwers E, Brown K, Baugh B, AMBER and EMERALD study groups.

Open source

DOI: 10.1080/25787489.2020.1844520
Published: 2020-12-01
Container: HIV Res Clin Pract
Publisher: Taylor & Francis
Open access: no

Credibility signals

uncertain Score 59/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/25787489.2020.1844520,
  title = {Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.},
  author = {Huhn GD and  Wilkin A and  Mussini C and  Spinner CD and  Jezorwski J and  El Ghazi M and  Van Landuyt E and  Lathouwers E and  Brown K and  Baugh B and  AMBER and EMERALD study groups.},
  year = {2020},
  journal = {HIV Res Clin Pract},
  doi = {10.1080/25787489.2020.1844520},
  url = {https://doi.org/10.1080/25787489.2020.1844520}
}

RIS

TY  - JOUR
TI  - Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
AU  - Huhn GD
AU  -  Wilkin A
AU  -  Mussini C
AU  -  Spinner CD
AU  -  Jezorwski J
AU  -  El Ghazi M
AU  -  Van Landuyt E
AU  -  Lathouwers E
AU  -  Brown K
AU  -  Baugh B
AU  -  AMBER and EMERALD study groups.
PY  - 2020
JO  - HIV Res Clin Pract
DO  - 10.1080/25787489.2020.1844520
UR  - https://doi.org/10.1080/25787489.2020.1844520
ER  -

APA

GD, H., A, W., C, M., CD, S., J, J., M, E. G., E, V. L., E, L., K, B., B, B., & groups., A. A. E. S. (2020). Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.. HIV Res Clin Pract. https://doi.org/10.1080/25787489.2020.1844520

Source records

europe-pmc · retrieved 2026-09-25T07:49:32.737Z
datacite · retrieved 2026-09-25T07:49:32.737Z
datacite · retrieved 2026-09-25T07:49:32.737Z
doaj · retrieved 2026-09-25T07:49:32.716Z